Studies preclinical

Huntington s disease is a familial and i ai e inherited neurological disorder affecting up to  

HD involves all ethnic groups and is most frequent in patients of Caucasian descent. 

The halhnai k of HD pathology is the regional atrophy and neuronal loss in the brain stem. 

A triad of major clinical finding characterizes disease abnonnal involuntai y movements, personality/behavioral disorders, and cognitive deteiioration. 

Ocular, orofacial and speech abnonnalities are not part of the HD disease complex. 

What is true about the national history and epidemiology of HD  

---

Immunosuppression induced by sirolimus (36) appears to be mediated by a mechanism distincdy different from that of either cyclosporin or FK-506. Sirolimus markedly suppresses IL-2 or IL-4-driven T-ceU proliferation. The preclinical studies suggest that sirolimus is a potent immunosuppressive agent in transplantation and autoimmune disease models. The clinical potential of this agent depends on its toxicity profile (80). 

CRH (Corticotropin releasing hormone) is expressed in the nucleus paraventricularis of the hypothalamus and drives the stress hormone system by activating synthesis and release of corticotropin at the pituitary and in turn corticosteroid from the adrenal cortex. CRH is also expressed at many other brain locations not involved in neuroendocrine regulation, e.g. the prefrontal cortex and the amygdala. Preclinical studies have shown that CRH also coordinates the behavioral adaptation to stress (e.g. anxiety, loss of appetite, decreased sleepiness, autonomic changes, loss of libido). 

Most recently, a phase-I-study defined a dose of 13-ris-retinoic acid that was tolerable in patients after myeloablative therapy, and a phase-III-trial showed that postconsolidation therapy with 13-cis-retinoic acid improved EFS for patients with high-risk neuroblastoma [7]. Preclinical studies in neuroblastoma indicate that ATRA or 13-cw-RA can antagonize cytotoxic chemotherapy and radiation, such that use of 13-cis-RA in neuroblastoma is limited to maintenance after completion of cytotoxic chemotherapy and radiation. It is likely that recurrent disease seen during or after 13-cis-RA therapy in neuroblastoma is due to tumor cell resistance to retinoid-mediated differentiation induction. Studies in neuroblastoma cell lines resistant to 13-cw-RA and ATRA have shown that they can be sensitive, and in some cases collaterally hypersensitive, to the cytotoxic retinoid fenretinide. Here, fenretinide induces tumor cell cytotoxicity rather than differentiation, acts independently from RA receptors, and in initial phase-I-trials has been well tolerated. Clinical trials of fenretinide, alone and in combination with ceramide modulators, are in development. 

CCI-779 - renal carcinoma, lymphoma AP23573 - sarcomas RAD-001 - pancreatic cancer Again, several preclinical studies suggest that rapalogs will have synergistic affects when used in combination with other chemotherapeutics. 

Kopf-Maier P, Kopf H (1988) Transition and Main-Group Metal Cyclopentadienyl Complexes Preclinical Studies on a Series of Antitumor Agnets of Different Structural... 

Preclinical studies have suggested that early thrombolysis, within 3.5 hours of arterial occlusion, resulted in neurological improvement with an acceptable risk of secondary central nervous system hemorrhage. ... 

Abbas, S. Bhoumik, A. Dahl, R. Vasile, S. Krajewski, S. Cosford,N. D. P. Ronai,Z. A. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 2007, 13, 6769-6778. 

Preclinical studies suggest mold-active azoles plus echinocandins have enhanced activity against Aspergillus A. terreus should be considered resistant to amphotericin B Activity of amphotericin B and voriconazole is decreased versus Aspergillus species higher doses or combination therapy may be indicated in more refractory cases... 

To determine whether human testing for a new drug or new drug product is reasonable, it is first necessary to conduct preclinical studies and to submit the IND. The necessary information needed to prepare the IND is outlined in Table 1. The IND is to contain information on appropriate prior animal studies for safety evaluation, any available clinical data, adequate drug identification and manufacturing instructions, and a detailed outline of the proposed clinical study, routs of administration, approximate number of patients to be used, and an estimate of the length of treatment and an environmental impact statement. 

The last step of the drug discovery process involves the testing of lead compounds to address issues such as efficacy, bioavailability, and safety. Testing may include in vitro assays but ultimately would require a suitable disease model and studies in animals. Many compounds may need to be designed and synthesized to identify the one compound with all the desired properties. Such a compound can be advanced to preclinical studies and eventually to the clinic. 

From the detail shown above, it is easy to see why drag discovery and development is such a costly process. One drag in every 5000-10000 entering preclinical studies makes it to the clinic. A recent estimate put the cost of bringing one drag to market as US 500 million [75], and up to 70% of that cost is associated with compound failures in these studies. DiMasi et al. have suggested that reductions... 

While the role of PHD inhibitors in the treatment of anemia is now validated, therapeutic validation is less certain in other HIF-associated pathologies such as wound healing, ulcerative colitis, therapeutic angiogenesis, and treatment of acute ischemic events such as myocardial ischemia and stroke. All of these indications are supported by a compelling array of in vitro and in vivo preclinical studies but their utility in the clinical setting remains to be evaluated and represents exciting possibilities for the future of small-molecule inhibitors of PHD enzymes. 

---